Evidence map›Paper›PMID 38012788›Full record

ArticleActa neuropathologica communications2023

Genetic alterations that deregulate RB and PDGFRA signaling pathways drive tumor progression in IDH2-mutant astrocytoma.

Kensuke Tateishi, Yohei Miyake, Taishi Nakamura, Hiromichi Iwashita, Takahiro Hayashi, Akito Oshima, Hirokuni Honma, Hiroaki Hayashi, Kyoka Sugino, Miyui Kato and 6 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neuropathologica communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Kensuke TateishiDepartment of Neurosurgery, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa, Yokohama, 2360004, Japan. ktate12@yokohama-cu.ac.jp.ORCID 0000-0001-6895-9013
Yohei MiyakeDepartment of Neurosurgery, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa, Yokohama, 2360004, Japan.
Taishi NakamuraDepartment of Neurosurgery, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa, Yokohama, 2360004, Japan.
Hiromichi IwashitaDepartment of Pathology, Yokohama City University Hospital, Yokohama, Japan.
Takahiro HayashiDepartment of Neurosurgery, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa, Yokohama, 2360004, Japan.
Akito OshimaDepartment of Neurosurgery, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa, Yokohama, 2360004, Japan.
Hirokuni HonmaDepartment of Neurosurgery, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa, Yokohama, 2360004, Japan.
Hiroaki HayashiNeurosurgical-Oncology Laboratory, Yokohama City University, Yokohama, Japan.
Kyoka SuginoDepartment of Neurosurgery, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa, Yokohama, 2360004, Japan.
Miyui KatoLaboratory of Biopharmaceutical and Regenerative Science, Graduate School of Medical Science, Yokohama City University, Yokohama, Japan.
Kaishi SatomiDepartment of Pathology, Kyorin University School of Medicine, Tokyo, Japan.
Satoshi FujiiDepartment of Diagnostic Pathology, Yokohama City University Hospital, Yokohama, Japan.
Takashi KomoriDepartment of Laboratory Medicine and Pathology (Neuropathology), Tokyo Metropolitan Neurological Hospital, Tokyo, Japan.
Tetsuya YamamotoDepartment of Neurosurgery, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa, Yokohama, 2360004, Japan.
Daniel P CahillDepartment of Neurosurgery, Massachusetts General Hospital, Boston, MA, USA.
Hiroaki WakimotoDepartment of Neurosurgery, Massachusetts General Hospital, Boston, MA, USA.
Yokohama City University · JPMassachusetts General Hospital · USYokohama City University Hospital · JPKyorin University · JPTokyo Metropolitan Neurological Hospital · JPYokohama City University Medical Center · JP

Funding

Japan Society for the Promotion of Science 19K09488Japan Society for the Promotion of Science 22K09210
6 · The paper itself

Abstract

In IDH-mutant astrocytoma, IDH2 mutation is quite rare and biological mechanisms underlying tumor progression in IDH2-mutant astrocytoma remain elusive. Here, we report a unique case of IDH2 mutant astrocytoma, CNS WHO grade 3 that developed tumor progression. We performed a comprehensive genomic and epigenomic analysis for primary and recurrent tumors and found that both tumors harbored recurrent IDH2

Indexed as

AstrocytomaBrain NeoplasmsReceptor, Platelet-Derived Growth Factor alphaRetinoblastoma ProteinAnimalsHomozygoteHumansIsocitrate DehydrogenaseMiceMutationRetinoblastoma Binding ProteinsSequence DeletionSignal TransductionUbiquitin-Protein LigasesIsocitrate DehydrogenaseRB1 protein, humanReceptor, Platelet-Derived Growth Factor alphaRetinoblastoma Binding ProteinsRetinoblastoma ProteinUbiquitin-Protein LigasesAstrocytomaIDH2 mutationMalignant phenotypePDX

Identifiers

PMID38012788
PMCPMC10680361
OpenAlexW4389051463

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.